Vertex Pharmaceuticals Inc.
VRTX NMS
Pharmaceuticals
Boston, MA
Pharmaceuticals
Boston, MA
2017 IW US 500 Rank | 409 |
2016 IW US 500 Rank | 517 |
Executive 1 | Jeffrey Leiden, Chairman; President |
Executive 2 | Michael Parini, Executive Vice President; Chief Legal Officer |
2016 Revenue (US$ Millions) | $1,702 |
Revenue Growth (%) | 64.89% |
2015 Revenue (US$ Millions) | $1,032 |
Net Income (US$ Millions) | ($112) |
Common Shares Outstanding (Millions) | 248.3 |
Earnings Per Share (US$) | ($0.46) |
Price to Earnings Ratio | N/A |
Total Equity (US$ Millions) | $1,157 |
Return on Equity (%) | -11.92% |
Long Term Debt (US$ Millions) | $521 |
Debt to Equity Ratio (%) | 0.45% |
Market Capitalization (US$ Millions) | $18,292 |
Total Assets (US$ Millions) | $2,897 |
Current Assets (US$ Millions) | $1,832 |
Inventories (US$ Millions) | $78 |
Current Liabilities (US$ Millions) | $793 |
Cost Of Goods Sold (US$ Millions) | $207 |
Asset Turnover | 0.63 |
Inventory Turnover | 3.07 |